.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to enhanced progression-free and overall survival, leading to FDA approval as well as a brand-new procedure choice for individuals.